{'fraction_non_alphanumeric': 0.033925686591276254, 'fraction_numerical': 0.033117932148626815, 'mean_word_length': 5.014563106796117, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Persistence of Pneumococcal Antibodies After Primary Immunisation With a Polysaccharide–Protein Conjugate Vaccine

P Zimmerman, KP Perrett, G Berbers, N Curtis. Arch Dis Child. 2019;104(7):680–684

The pneumococcal polysaccharide-protein conjugate vaccine (PCV) is a part of the primary vaccination series recommended by the World Health Organization (WHO) as well as the Centers for Disease Control and Prevention (CDC). The purpose of this study was to examine the protective antibody response at 7 and 13 months to PCV by following the primary vaccination series recommended by the WHO, using the 3 + 0 schedule (PCV at 6 weeks, 3–4 months, and 4–6 months of age).

Patients were gathered from a previous patient population that was a part of the Melbourne Infant Study: BCG for Allergy and Infection Reduction that was looking at BCG immunization at birth and the protective nature against allergy, childhood infection, and asthma from whom blood samples were collected at 7 and/or 13 months of age. All of these infants were in Melbourne, Australia, and were a part of the Australian National Immunization program from 2013 to 2016. Inclusion criteria were infants born at >32 weeks’ gestation, birth weight >1500 g, mother who was …